舒肝解郁胶囊治疗卒中后抑郁的临床研究  

Efficacy of Shuganjieyu capsule for the treatment of Post-stroke depression

作　　者：毛森林[1] 罗莎[2] 

机构地区：[1]哈尔滨医科大学附属第二医院神经内科,哈尔滨150086 [2]黑龙江省森工总医院,哈尔滨150040

出　　处：《临床药物治疗杂志》2016年第1期54-56,共3页Clinical Medication Journal

摘　　要：目的:观察舒肝解郁胶囊治疗卒中后抑郁的疗效和副反应。方法:将120例卒中后抑郁病人随机分为治疗组和对照组,两组病人均给予脑梗死常规治疗,治疗组服用舒肝解郁胶囊,对照组服用氟西汀胶囊,疗程8周。分别于治疗前,治疗第2,4,8周末采用汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)评定疗效和不良反应。结果:至研究终点,两组HAMD评分均显著低于治疗前(P<0.05),但两组间比较差异无统计学意义(P>0.05);治疗组和对照组有效率分别为86.67%,83.33%,差异无统计学意义(P>0.05);治疗组的TESS评分显著低于对照组(P<0.05)。结论:舒肝解郁胶囊治疗卒中后抑郁与氟西汀相当,疗效确切,不良反应明显少于后者。Objective： To observe the clinical evaluation and side effects of shuganjieyu capsule for treatment of post-stroke depression. Methods： A total of 120 patients with post-stroke depression were randomly divided into the treatment group and the control group. The treatment group was treated with Shuganjieyu capsule, and the control group was treated with Fluoxetine for 8 weeks, Two groups were almost equal on the basis of routine treatment. The therapeutic efficacy and adverse reactions were evaluated at the beginning and by the end of 2-,4-,8-week after treatment by Hamilton Depression Scale （HAMD） and Treatment Emergent Symptoms Scale （TESS）. Results： By the end of study, the scores of HAMD were significantly lower than those at the beginning （P〈0.05）, and no statistically significant difference was found between two groups （P〉0.05）; the effective ratios of the treatment group and the control group were 86.67% and 83.33% respectively with no statistically significant difference between two groups too （P〉0.05）; The TESS was conspicuously fewer in the test group than that in the control group （P〈0.05）. Conclusion： Shuganjieyu capsule presents the similar effect as Fluoxetine in treating post-stroke depression patients with less side effects.

关 键 词：舒肝解郁胶囊 卒中后抑郁 氟西汀 

分 类 号：R743[医药卫生—神经病学与精神病学]